Home Online Features Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Press Releases
Immunic, Inc.  
May 1, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of

The Bradford Era

Local & Social
Latest news for you
ePaper
google_play
app_store
This Week's Ads
Current e-Edition
ePaper
google_play
app_store
Already a subscriber? Click the image to view the latest e-edition.
Don't have a subscription? Click here to see our subscription options.
Mobile App

Download Now

The Bradford Era mobile app brings you the latest local breaking news, updates, and more. Read the Bradford Era on your mobile device just as it appears in print.

ePaper
google_play
app_store
Trending Recipes

Help Our Community

Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!

Get in touch with The Bradford Era
Submit Content
Advertise
Subscribe
Illinois
Indiana
Iowa
Michigan
New York
Pennsylvania
© Copyright The Bradford Era 43 Main St, Bradford, PA  | Terms of Use  | Privacy Policy
Powered by TECNAVIA